BLAINJECTIONINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO QVANTIG is a subcutaneous formulation of nivolumab, a PD-1 checkpoint inhibitor, combined with hyaluronidase to enable rapid subcutaneous administration. This combination maintains the immunooncology efficacy of intravenous nivolumab while offering patients improved convenience through reduced infusion time. The product treats patients with various cancers who benefit from PD-1 pathway inhibition.
Growth
As a newly approved formulation of an established franchise, OPDIVO QVANTIG enters a growth phase with moderate competitive pressure (30/100), creating opportunities for brand expansion and market penetration teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Started Aug 2025
200 enrolled
Cancer
Career Relevance
Working on OPDIVO QVANTIG positions you on a high-profile oncology franchise with established clinical credibility and patient need. The formulation innovation focus creates career pathways in brand building, patient access, and specialty pharma execution rather than novel drug development.
Brand Manager
Worked on OPDIVO QVANTIG at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.